Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
De-risking antibody discovery through comprehensive developability profiling
De-risking antibody discovery through comprehensive developability profiling Download Tech Note Contact Us Select leads with confidence by integrating biophysical assays, computational analysis, and clinical benchmarking from the earliest stages of discovery. Despite strong target binding, many therapeutic antibodies fail late in development due to preventable issues related to stability, manufacturability, or pharmacokinetics. Alloy’s integrated developability […]
Poster | A Fully Integrated GPCR Antibody Discovery Workflow
Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow Download the poster Contact Us Poster Overview: Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAbTM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
New Data: unlocking the potential of TCRm antibodies Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies. Download the poster Contact Us Keyway™ TCRm antibody discovery platform is revolutionizing immunotherapy development In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Webinar Overview: Discover how to access previously untapped sources of high-affinity antibodies. In this presentation, Dr. Joe de Rutte from Partillion Bioscience and Dr. Dilip Challa from Alloy Therapeutics discuss how breakthrough technology can help: Access Plasma Cell Diversity: Discover how nanovial technology enables screening of plasma cells from ATX-GK transgenic mice harboring fully human […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]